RxDoctor Payments DataLook up a doctor →

Sonya Tatum

Adult Health · Montgomery, ALNPI 1760755433

Payments from drug & device makers

$9,145in general payments, 2019–2025

Across 582 payments — averaging $15.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$740
  • Amgen$547
  • Astellas Pharma US Inc$531
  • Lilly USA, LLC$511
  • Johnson & Johnson$504
  • plus $5K from 52 others

What the payments were for

  • Food & beverage$8,97898%
  • Education$1672%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie93$1,101
Novo Nordisk44$740
Amgen31$547
Astellas Pharma US Inc23$531
Lilly USA, LLC40$511
Johnson & Johnson42$504
Pfizer31$446
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC23$399
AstraZeneca22$398
Otsuka America Pharmaceutical, Inc.21$368
Bayer21$364
GSK14$241
Sumitomo Pharma America, Inc.16$240
Novartis14$213
Takeda Pharmaceuticals U.S.A., Inc.10$200
Merck12$188
Biohaven Pharmaceutical Holding Company Ltd.8$145
Biohaven Pharmaceuticals, Inc.7$126
Axsome Therapeutics, Inc.6$118
Mylan Specialty L.p.6$113
IBSA Pharma Inc.7$112
Lundbeck LLC5$103
Abbott5$98
Arbor Pharmaceuticals, Inc.6$95
Idorsia Pharmaceuticals US Inc5$93
Exact Sciences5$83
Boehringer Ingelheim6$77
Sanofi-aventis U.S. LLC4$71
Neurocrine Biosciences, Inc.4$67
Nestle Healthcare Nutrition Inc.3$64
Esperion Therapeutics, Inc.4$58
Ironwood Pharmaceuticals, Inc3$50
Clarus Therapeutics Inc.3$50
Sunovion Pharmaceuticals Inc.6$50
Dexcom, Inc.3$47
Ardelyx, Inc.2$46
Antares Pharma, Inc.2$41
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$39
Evoke Pharma, Inc.2$36
Corcept Therapeutics2$36
Amarin Pharma, Inc.2$33
Inspire Medical Systems, Inc.1$30
Seqirus USA Inc1$25
Teva Pharmaceuticals USA, Inc.1$23
Biogen1$21
Harmony Biosciences LLC1$21
Tolmar, Inc.1$18
Inogen, Inc.1$17
Scilex Pharmaceuticals Inc.1$16
E.r. Squibb & Sons, L.L.C.1$16
SK Life Science, Inc.1$16
Supernus Pharmaceuticals, Inc.1$15
Phathom Pharmaceuticals, Inc.1$15
Kowa Pharmaceuticals America, Inc.1$15
Currax Pharmaceuticals LLC1$14
Medicure Pharma Inc.1$14
Upsher-smith Laboratories LLC1$13
Eisai Inc.1$13

How this compares

$9,145 in reported general payments places this provider in the 95th percentile of 308 adult health providers in Alabama.

See all adult health providers in Alabama

Medicare billing

Part B allowed, 2024
$25,357
Medicare patients
134
Services billed
291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin68$71,791
EliquisApixaban43$39,395
OzempicSemaglutide29$29,026
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$23,927
JanuviaSitagliptin Phosphate20$21,930
MyrbetriqMirabegron25$17,693
RybelsusSemaglutide11$16,781
MounjaroTirzepatide16$16,411
LinzessLinaclotide19$12,164
TrulicityDulaglutide11$12,102
XareltoRivaroxaban13$10,768
Spiriva RespimatTiotropium Bromide14$7,554
EntrestoSacubitril/Valsartan11$7,084
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,455
Rosuvastatin Calcium150$4,376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$77$79,34682 claims
Novo NordiskOzempic, Rybelsus$740$45,80840 claims
PfizerEliquis$446$39,39543 claims
GSKTrelegy Ellipta, Anoro Ellipta$241$29,38241 claims
Lilly USA, LLCMounjaro, Trulicity$511$28,51427 claims
MerckJanuvia$188$21,93020 claims
Astellas Pharma US IncMyrbetriq$531$17,69325 claims
AbbVieLinzess, Synthroid$1,101$15,10646 claims
Johnson & JohnsonXarelto$504$10,76813 claims
NovartisEntresto$213$7,08411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 adult health providers in Alabama.

Other adult health in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →